Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
40 results about "Drug resistant tuberculosis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Extensively drug-resistant tuberculosis (XDR-TB) is a newly described category of TB that is resistant to fluoroquinolone (a strong antibiotic like ciprofloxacin) and capreomycin, kanamycin, or amikacin, drugs currently used for MDR-TB. XDR-TB is extremely difficult to treat.
Method and kit for detecting multi-drug resistant mycobacterium tuberculosis (MDR-TB)
ActiveCN101845503AAccurate Diagnostic InformationShorten the timeMicrobiological testing/measurementFluorescence/phosphorescenceMulti-drug-resistant tuberculosisGenes mutation
The invention relates to a method adopting double-label probe detection and melting curve analysis for diagnosing the infection of multi-drug resistant mycobacterium tuberculosis and a kit which utilizes the method to detect multiple gene mutations related to drug resistant tuberculosis at the same time, and the invention belongs to the life science and biological technical field. The kit of the invention contains a primer designed for multiple gene mutations related to drug resistant, a double-label oligonucleotide probe capable of detecting multiple common gene mutation sites related to drug resistant tuberculosis and a DNA polymerases with heat stability and without 5' nuclease activity, and the kit can be used to detect at least 16 common gene mutation sites related to drug resistant tuberculosis under proper PCR reaction conditions. The detection method and kit of the invention can be used in the early diagnosis of multi-drug resistant tuberculosis and overcome the problems of the existing technology that the detection time is long, a great deal of manpower and large material resources are needed, the detection cost is high, etc.
Owner:无锡锐奇基因生物科技有限公司
Pharmaceutical composition for treating drug-resistant tuberculosis
ActiveCN103357016AGood treatment effectAntibacterial agentsOrganic active ingredientsAntituberculosis drugCurative effect
The invention relates to an artemisinin pharmaceutical composition, and particularly relates to a composition of nano chitosan artemisinin and antituberculosis drugs, used for treating drug-resistant tuberculosis. The pharmaceutical composition comprises the following effective components: the antituberculosis drugs, the nano chitosan artemisinin, three nano chitosan artemisinin derivatives or artemisinin and a derivative of artemisinin, wherein the nano chitosan artemisinin is prepared from the following ingredients by weight percent: 40-805 of artemisinin or artemisinin derivatives, 1-5% of polyvinyl pyrrolidone and 15-50% of nano chitosan. Artemisinin drugs, the nano chitosan artemisinin and derivatives, and the antituberculosis drugs are used as the pharmaceutical composition, so that drug-resistant tubercle bacillus can be inhibited and killed; and the pharmaceutical composition has a prominent curative effect on the drug-resistant tuberculosis.
Owner:四川绵阳四〇四医院
Catechu extract composition for resisting tubercle bacillus, preparation method of catechu extract composition, pharmaceutical preparation containing catechu extract composition, and application of catechu extract composition
InactiveCN102526170AHigh effective contentGood treatment effectAntibacterial agentsOrganic active ingredientsTherapeutic effectStructural formula
The invention discloses a catechu extract composition for resisting tubercle bacillus, a preparation method of the catechu extract composition, a pharmaceutical preparation containing the catechu extract composition, and application of the catechu extract composition. The catechu extract composition contains a flavanoid compound of which the purity is more than 50%, and the flavanoid compound takes catechin and / or epicatechin as main components. The main structural formulas (I) and (II) of the flavanoid compound are shown in the specifications, wherein R1, R2, R3, R4 and R5 are respectively and independently selected from hydrogen, C1-C6 alkyl, beta-D-glucopyranesyl, SO3 or PO3. By adopting a chromatographic process for refining and purifying the catechu extract composition disclosed by the invention, the effective content is as high as 99.5%. The catechu extract composition and the pharmaceutical composition thereof have excellent effects on improving or treating pulmonary tuberculosis, treating ulcerative bone tuberculosis and AIDS (Acquired Immune Deficiency Syndrome) complicated by tuberculosis, treating drug resistant tuberculosis, and especially treating drug resistant tuberculosis and AIDS complicated by tuberculosis.
Owner:许学志
Propylene tethered ciprofloxacin-isatin hybrids as well as synthetic method and application thereof
InactiveCN108727332AStrong drug resistanceStrong resistanceAntibacterial agentsOrganic active ingredientsMulti-drug-resistant tuberculosisIsoniazid
The invention discloses propylene tethered ciprofloxacin-isatin hybrids as well as a synthetic method and an application thereof. The prepared ciprofloxacin-isatin hybrid 3d have strong resistance toall tested Gram-positive bacteria and Gram-negative bacteria (including pathogens showing strong drug resistance clinically), and efficacy of 3d is equivalent to or even better than the parent ciprofloxacin or levofloxacin; antibacterial activity of hybrid 3b (MIC: 0.10 and 0.5 mu g / mL) for an mycobacterium tuberculosis H37Rv strain is 4 times and 8 times that of ciprofloxacin (MIC: 0.78 mu g / mL)and rifampicin (MIC: 0.39 mu g / mL), and antibacterial activity of the hybrid 3b for multi-drug resistant tuberculosis is 4->256 times that of three reference drugs including ciprofloxacin (MIC: 2.0 mug / mL), rifampicin (MIC: 32 mu g / mL) and isoniazid (>128 mu g / mL). The hybrids 3b and 3d with lower cytotoxicity (CC50: 64 and 256 mu g / mL) show acceptable metabolic stability and in-vivo PK (pharmacokinetics) characteristics.
Owner:王若
Novel biological agent for treating drug resistant tuberculosis and preparation method thereof
ActiveCN107812013AImprove the quality of lifeAppetite weight gainAntibacterial agentsCulture processAntigenDisease
The invention belongs to the technical field of biological agents and discloses a novel biological agent for treating drug resistant tuberculosis and a preparation method thereof. The novel biologicalagent for treating drug resistant tuberculosis is a tuberculosis specific lymphocyte and is prepared by utilizing IL-1 alpha, IL-2, a CD3 monoclonal antibody and tuberculosis specific antigens (CFP10, ESAT6). Compared with the conventional tuberculosis treatment method, the novel biological agent disclosed by the invention is reported for the first time at home and abroad, and obvious curative effects are achieved when patients with pulmonary tuberculosis are treated by utilizing lymphocytes cultured in vitro. For patients subjected to cell therapy, the number of lymphocytes in peripheral blood is obviously increased, the sputum examination result is rapidly turned to be negative, pulmonary shadow is rapidly absorbed, the course of disease is shortened, the mental state is improved, and the appetite and weight are increased. The living quality of the patients in anti-tuberculosis therapy is obviously improved.
Owner:苏州市第五人民医院
Fusion protein and its use in treatment on disease
ActiveCN106552259AHas the effect of treating tuberculosisAvoid drug resistanceAntibacterial agentsOrganic active ingredientsDiseaseDrug resistance
The invention provides a fusion protein and its use in treatment on tuberculosis. The fusion protein can realize targeting and specific induction of apoptosis of macrophages with the function of phagocytosis of tubercle bacillus, can kill intracellular bacterial parasite and does not induce bacterial drug resistance. The fusion protein plays an important role in treatment on drug-resistant tuberculosis.
Owner:中国科学院上海免疫与感染研究所
Isoniazid caffeic acid amidated derivative and application thereof in anti-mycobacterium tuberculosis drug
InactiveCN104926721AInhibition of drug-resistant tuberculosisInhibition against liver damageAntibacterial agentsOrganic chemistryIsoniazidMetabolic rate
The present invention belongs to the technical field of medicines, discloses an isoniazid caffeic acid amidated derivative as follows: (E)-N '-(3-(3,4-dihydroxyphenyl) acryloyl) isoniazid, and also discloses a method for preparing the derivative. Isoniazid is a commonly-used first-line anti-tuberculosis drug, but the isoniazid has the shortcomings of being fast in metabolic rate, low in producing tendency of drug resistance, and low in tendency to cause liver injury, and the like. The present invention discloses the isoniazid caffeic acid amidated derivative (E)-N '-(3-(3,4-dihydroxyphenyl) acryloyl) isoniazid, and solves the problems that the isoniazid derivative in the prior art cannot effectively suppress drug-resistant mycobacterium tuberculosis, and has low tendency to cause liver injury, and the like, the drug-resistant mycobacterium tuberculosis inhibiting activity of the isoniazid derivative is higher than that of isoniazid, the isoniazid derivative has low tendency to cause liver injury, compared with the first-line anti-tuberculosis drug isoniazid, the isoniazid derivative has a dual effect, can be used for the treatment of drug-resistant tuberculosis, and provides a new choice for the preparation of anti-tuberculosis drugs.
Owner:LANZHOU UNIVERSITY
Use of compound AG120 or pharmaceutically acceptable salt thereof in preparation of drug for prevention or treatment of tuberculosis
ActiveCN109224061AAvoid infectionHuge market potentialAntibacterial agentsDipeptide ingredientsTuberculosis bacillusPulmonary tuberculosis
The invention belongs to the technical field of pharmaceutical chemistry, and especially relates to use of compound AG120 or pharmaceutically acceptable salt thereof in preparation of drug for prevention or treatment of tuberculosis, and a pharmaceutical composition for preventing or treating tuberculosis. The compound AG120 can effectively inhibit the infection of tuberculosis bacillus, thereby providing effective drug support for the prevention or treatment of tuberculosis. Therefore, the present invention discloses compound AG120 which can be used as a lead compound for preventing or treating tuberculosis, and has the activity of anti-tuberculosis bacteria and drug-resistant tuberculosis bacteria, and is particularly suitable for preventing or treating tuberculosis, thus having wide clinical application prospect and great market potential.
Owner:SHANGHAI PULMONARY HOSPITAL
Pharmaceutical composition, use of mefloquine in a fixed dose, and method for treating tuberculosis
ActiveUS20180318283A1Effective treatmentAntibacterial agentsDispersion deliveryMulti-drug-resistant tuberculosisTreating tuberculosis
This invention concerns the use of mefloquine in relation to Mycobacterium tuberculosis. This invention also concerns the combination of mefloquine with drugs used in first and second choice treatment of tuberculosis, achieving a reduction in the treatment period of tuberculosis (TB) and the treatment of multi-drug resistant tuberculosis (MDR-TB).
Owner:FUNDACAO OSWALDO CRUZ FIOCRUZ
Quick effective medicine specified for treating drug resistant tuberculosis
InactiveCN1628755AGood effectHigh cure rateAntibacterial agentsUnknown materialsMedicinal herbsMedicine
The invention provides a quick effective medicine specified for treating drug resistant tuberculosis, which is prepared from traditional medicinal herbs including roor of sessile stemona 10-30 parts, root of red rooted saliva 10-30 parts, donkey-hide gelatin 10-30 parts, radix scrophulariae 25-75 parts.
Owner:李长军
RelA cut and TLR7 active sequence modified locked nucleic acid deoxyribozyme for targeted therapy of tuberculosis and application thereof
ActiveCN103243098ANo obvious side effectsIncrease lethalityAntibacterial agentsGenetic material ingredientsNucleotideMolecular Targeted Therapies
The invention discloses RelA cut and TLR7 active sequence modified locked nucleic acid deoxyribozyme for targeted therapy of tuberculosis. A nucleotide sequence is one of SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:3. The invention simultaneously discloses use of the RelA cut and TLR7 active sequence modified locked nucleic acid deoxyribozyme for targeted therapy of tuberculosis in a drug for treating latent infection caused by L-type mycobacterium tuberculosis. By adopting the RelA cut and TLR7 active sequence modified locked nucleic acid deoxyribozyme, the advantages of effects of gene therapy and immunological therapy are integrated; and the therapeutical effect is played specifically aiming at drug-resistant tuberculosis of infection in the body, especially the L-type mycobacterium tuberculosis.
Owner:WEIFANG MEDICAL UNIV
Formula of traditional Chinese medicine for treating drug-resistant tuberculosis, and preparation method of traditional Chinese medicine
InactiveCN106620454ANo obvious side effectsPromote absorptionAntibacterial agentsPlant ingredientsSide effectRadix Astragali seu Hedysari
The invention discloses a formula of a traditional Chinese medicine for treating drug-resistant tuberculosis, and a preparation method of the traditional Chinese medicine, belonging to the technical field of medicines. The formula comprises the following raw materials in parts by weight: 5-10 parts of radix astragali seu hedysari, 3-5 parts of calyx seu fructus physalis, 3-6 parts of radix stemonae, 3-6 parts of radix et rhizoma rhei, 5-10 parts of rhizoma bletillae, 5-8 parts of herb of Russian boschniakia, 3-10 parts of radix ranunculi ternati, 5-12 parts of spica prunellae, 4-12 parts of fructus schisandrae, 3-10 parts of Chinese asafoetida, 2-5 parts of common sowthistle herb, 2-10 parts of unibract fritillary bulb, 3-10 parts of liquorice root and 3-8 parts of Indian damnacanthus herb. The formula of the traditional Chinese medicine for treating the drug-resistant tuberculosis is scientific in compatibility of medicines, and has a good curative effect for the drug-resistant tuberculosis; furthermore, the traditional Chinese medicine is quick in response, does not easily cause relapse, is basically free from toxic and side effects and is low in price, thus having a great promotional value.
Owner:THE FIRST AFFILIATED HOSPITAL OF XINXIANG MEDICAL UNIV
Pyrazolo[1,5‑a]pyridine compounds and their applications
ActiveCN105524058BEnhanced inhibitory effectGood in vitro anti-tuberculosis activityAntibacterial agentsOrganic active ingredientsMulti-drug-resistant tuberculosisInfectious dose
Disclosed in the invention are a pyrazolo[1,5-a]pyridine compound with the structural features as shown in formula (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug molecule thereof and a use thereof. Such compounds have a good in vitro antituberculosis activity, and the minimal inhibitory concentration (MIC) of the compounds is lower than 0.1 μg / mL and partially achieves 0.01 μg / mL, and have a very strong inhibiting effect on clinically selected multi-drug resistant tuberculosis (MDR-TB) strains. In an in vivo experiment, the pyrazolo[1,5-a]pyridine compounds of the present invention can effectively scavenge the infectious dose of H37Ra in a mouse body at 20mg / kg / d doses, thereby being a new type of antituberculosis compound.
![Pyrazolo[1,5‑a]pyridine compounds and their applications](https://images-eureka.patsnap.com/patent_img/0cd158b7-ce25-4014-b4b4-a23bbadeed81/HDA0000770441560000011.png "Pyrazolo[1,5‑a]pyridine compounds and their applications")
![Pyrazolo[1,5‑a]pyridine compounds and their applications](https://images-eureka.patsnap.com/patent_img/0cd158b7-ce25-4014-b4b4-a23bbadeed81/HDA0000770441560000012.png "Pyrazolo[1,5‑a]pyridine compounds and their applications")
![Pyrazolo[1,5‑a]pyridine compounds and their applications](https://images-eureka.patsnap.com/patent_img/0cd158b7-ce25-4014-b4b4-a23bbadeed81/HDA0000770441560000021.png "Pyrazolo[1,5‑a]pyridine compounds and their applications")
Owner:GUANGDONG GOOD MEDICINE & HEALTH TECH CO LTD
Kit for detecting drug resistant mycobacterium tuberculosis (MDR-TB)
ActiveCN101845503BAccurate Diagnostic InformationShorten the timeMicrobiological testing/measurementFluorescence/phosphorescenceMulti-drug-resistant tuberculosisMycobacterium Infections
The invention relates to a method adopting double-label probe detection and melting curve analysis for diagnosing the infection of multi-drug resistant mycobacterium tuberculosis and a kit which utilizes the method to detect multiple gene mutations related to drug resistant tuberculosis at the same time, and the invention belongs to the life science and biological technical field. The kit of the invention contains a primer designed for multiple gene mutations related to drug resistant, a double-label oligonucleotide probe capable of detecting multiple common gene mutation sites related to drug resistant tuberculosis and a DNA polymerases with heat stability and without 5' nuclease activity, and the kit can be used to detect at least 16 common gene mutation sites related to drug resistant tuberculosis under proper PCR reaction conditions. The detection method and kit of the invention can be used in the early diagnosis of multi-drug resistant tuberculosis and overcome the problems of the existing technology that the detection time is long, a great deal of manpower and large material resources are needed, the detection cost is high, etc.
Owner:无锡锐奇基因生物科技有限公司
Medicine for treating pulmonary tuberculosis and its preparing process
InactiveCN100528207CSimple recipeLow costAntibacterial agentsPharmaceutical delivery mechanismSide effectBULK ACTIVE INGREDIENT
Owner:连云港霞安贸易有限公司
Anti-drug resistant tuberculosis compound targeting bacteria RNA polymerase
InactiveCN103705518AEnhanced inhibitory effectAntibacterial agentsOrganic active ingredientsEscherichia coliProtein target
The invention belongs to the field of pharmacy and relates to an application of a small-molecule inhibitor for mycobacterium tuberculosis, escherichia coli and staphylococcus aureus RNA polymerase and shown by the formula (I) and an application of the compound in preparing a medicine for preventing or treating related bacterial infection diseases. The results of biochemical and biological experiments indicate that the inhibitor shown by the formula (I) has strong adhesion with the target protein, namely, the mycobacterium tuberculosis, escherichia coli and staphylococcus aureus RNA polymerase, and can obviously inhibit the activity of the polymerase and remarkably inhibit the growth of the mycobacterium tuberculosis (including drug-resistant mycobacterium tuberculosis), escherichia coli and staphylococcus aureus. The inhibitor provided by the invention also can be prepared into a disinfectant.
Owner:SICHUAN UNIV
Bacillus tubercle gene vaccine for treating medicine-tolerant pulmonary tuberculosis
InactiveCN101376025BEffective treatmentReduced lung pathologyAntibacterial agentsBacterial antigen ingredientsBacteroidesFhit gene
Owner:中国人民解放军总医院第二附属医院 +1
Pyrrole derivatives as antimycobacterial compounds
InactiveUS20050107370A1Low toxicityAntibacterial agentsBiocideMulti-drug-resistant tuberculosisAntimycobacterial
Novel pyrrole derivatives of formula (I) and their pharmaceutically acceptable acid addition salts having superior antimycobacterial activity against clinically sensitive as well as resistant strains of Mycobacterium tuberculosis as well as having lesser toxicity compared to known compounds. The use of the novel compounds of formula (I) for treatment of latent tuberculosis including Multi Drug Resistant Tuberculosis (MDR TB). The methods for preparation of the novel compounds, pharmaceutical compositions containing the novel compounds and method of treating MDR TB by administration of compounds of formula (I).
Owner:LUPIN LTD
Novel compound and medical compositions for treating tuberculosis comprising the same
InactiveCN108794372AHigh activityLow cytotoxicityAntibacterial agentsOrganic active ingredientsChemical compoundMedicine
The present invention relates to a compound represented by a Chemical Formula 2 and the use of the compound represented by the Chemical Formula 2 for the prevention or treatment of tuberculosis. The compound represented by Chemical Formula 2 having antitubercular activity is excellent in activity against a tuberculosis strain and a drug-resistant tuberculosis strain, has low cytotoxicity, and canbe used as a pharmaceutical composition for preventing or treating tuberculosis.
Owner:SOONCHUNYANG UNIV IND ACAD COOP FOUND
Medical application of n-(thiophene-2)amide derivatives in pyrazinamide-resistant tuberculosis and tuberculosis treatment
Owner:CHINA PHARM UNIV
Compound Chinese medicine comprising parasitic loranthus and mistletoe and its use
InactiveCN100536893CMitigate and reduce toxicityGood treatment effectAntibacterial agentsRespiratory disorderAntimicrobial drugTherapeutic effect
The invention belongs to the technical field of medicine, and specifically relates to a compound prescription composed of traditional Chinese medicines mulberry and mistletoe, a series of compound prescriptions derived from the combination of one or more other traditional Chinese medicines and the application thereof. These compounds have the functions of anti-tuberculosis, anti-inflammation, anti-infection, clearing the lungs and reducing phlegm, relieving cough and hemostasis, strengthening the heart and nourishing the lungs, and regulating immunity. They can be used alone or in combination with chemotherapy drugs and antibacterial drugs to treat tuberculosis, pulmonary heart disease, Pneumonia, acute and chronic bronchitis and other respiratory infectious diseases and syndromes are especially suitable for the treatment of drug-resistant and drug-resistant tuberculosis, which can alleviate and reduce the toxicity caused by chemotherapy and improve the therapeutic effect.
Owner:大理市阿佳咪白族医药研究所 +1
Catechu extract composition for resisting tubercle bacillus, preparation method of catechu extract composition, pharmaceutical preparation containing catechu extract composition, and application of catechu extract composition
InactiveCN102526170BHigh effective contentGood treatment effectAntibacterial agentsOrganic active ingredientsAdditive ingredientTherapeutic effect
The invention discloses a catechu extract composition for resisting tubercle bacillus, a preparation method of the catechu extract composition, a pharmaceutical preparation containing the catechu extract composition, and application of the catechu extract composition. The catechu extract composition contains a flavanoid compound of which the purity is more than 50%, and the flavanoid compound takes catechin and / or epicatechin as main components. The main structural formulas (I) and (II) of the flavanoid compound are shown in the specifications, wherein R1, R2, R3, R4 and R5 are respectively and independently selected from hydrogen, C1-C6 alkyl, beta-D-glucopyranesyl, SO3 or PO3. By adopting a chromatographic process for refining and purifying the catechu extract composition disclosed by the invention, the effective content is as high as 99.5%. The catechu extract composition and the pharmaceutical composition thereof have excellent effects on improving or treating pulmonary tuberculosis, treating ulcerative bone tuberculosis and AIDS (Acquired Immune Deficiency Syndrome) complicated by tuberculosis, treating drug resistant tuberculosis, and especially treating drug resistant tuberculosis and AIDS complicated by tuberculosis.
Owner:许学志
Phenothiazine derivatives and their use in treating pulmonary tuberculosis
InactiveCN104812394BAntibacterial agentsOrganic active ingredientsAntituberculous drugsPhenothiazine derivative
Tricyclic derivatives of formula (1) for antimicrobial agents, wherein R1 can be alkylsulfonate or sulfonamide. The derivatives are optionally substituted, wherein R2 is hydrogen, halogen, substituted alkyl, thioether or acetyl; Y can be N or C; X can be S, SO, SO2, N, O, CH2, C(O), CO2, NHCO, and Ring B is a 6-, 7-, or 8-membered cycloalkyl ring. The tricyclic derivatives, such as phenothiazine derivatives, can be used to treat pulmonary tuberculosis, especially drug-sensitive and drug-resistant pulmonary tuberculosis. The derivatives of the present invention may be used alone or in combination with known anti-tuberculosis drugs such as ethionamide and ethambutol, and the combination may be administered as a single dose or as two separate doses . The tricyclic derivatives can also be used in the manufacture of drugs for the treatment of tuberculosis.
Owner:UNIVERSITY OF CAPE TOWN
Pharmaceutical composition, use of mefloquine in fixed dose, and method for treating tuberculosis
ActiveUS10688088B2Antibacterial agentsDispersion deliveryTuberculosis mycobacteriumPharmaceutical drug
Owner:FUNDACAO OSWALDO CRUZ FIOCRUZ
Application of tsaoko amomum fruit extract
The invention discloses application of a tsaoko amomum fruit extract, and provides application of a tsaoko amomum fruit alcohol extract to preparation of drugs for drug-resistant tuberculosis, and application of the tsaoko amomum fruit alcohol extract to preparation of drugs for inhibiting drug-resistant mycobacterium tuberculosis. A Soxhlet extraction method is adopted, ethyl alcohol with the concentration being 80-100% is taken as a solvent, then tsaoko amomum fruit is heated, subjected to reflux extraction, filtered, concentrated, frozen and dried, and thus the tsaoko amomum fruit alcohol extract is obtained. Through experiments, it is proved that the tsaoko amomum fruit alcohol extract has the quite high antituberculous effect on mycobacterium tuberculosis, especially multiple-drug-resistant mycobacterium tuberculosis, in addition, through the cytotoxicity evaluation result of the tsaoko amomum fruit alcohol extract, it is proved that the tsaoko amomum fruit alcohol extract has noobvious cytotoxicity to human embryonic lung fibroblast MRC-5 when the concentration of the tsaoko amomum fruit alcohol extract is not greater than 250 [mu]g / mL, and therefore, the tsaoko amomum fruitextract is of important significance on development of drugs resisting tubercle bacillus, especially drug-resistant tubercle bacillus.
Owner:CAPITALBIO CORP
New modalities for treatment of drug-resistant tuberculosis and other diseases
InactiveUS20100204310A1Prevent bacterial growthInhibit expressionAntibacterial agentsOrganic active ingredientsRibosomal protein E-L30Disease
The invention provides antibacterial compounds comprising an oligonucleotide having a sequence complementary to a translation initiation region of an mRNA encoding a mycolyl transferase of Mycobacterum tuberculosis selected from protein 30, 32A and 32B, and further having 5′ and 3′ palindromic hairpin-forming sequences, said compound being covalently linked to a protein synthesis inhibiting antibiotic via a linker. The invention further provides pharmaceutical formulations of such compounds and methods of use thereof for treating tuberculosis. Other diseases may similarly be treated by tethering and antibiotic which targets a ribosomal protein to an antisense oligonucleotide complementary to an mRNA involved in the disease.
Owner:ZATA PHARM INC
Isotope enhanced ambroxol for long lasting autophagy induction
ActiveUS10583099B2Longer treatmentConvenient treatmentAntibacterial agentsPowder deliveryDiseaseActive agent
The present invention is directed to 2H isotope enhanced ambroxol (“isotope enhanced ambroxol”) and its use in the treatment of autophagy infections, especially mycobacterial and other infections, disease states and / or conditions of the lung, such as tuberculosis, especially including drug resistant and multiple drug resistant tuberculosis. Pharmaceutical compositions comprising isotope enhanced ambroxol, alone or in combination with an additional bioactive agent, especially rifamycin antibiotics, including an additional autophagy modulator (an agent which is active to promote or inhibit autophagy) are also disclosed. These compositions are useful against an autophagy mediated disease state and / or condition), especially an autophagy mediated disease state and / or condition which occurs in the lungs.
Owner:UNM RAINFOREST INNOVATIONS
Compound for inhibiting growth of tubercle bacillus and preparation method thereof
InactiveCN102001996AGrowth inhibitionEnhanced inhibitory effectAntibacterial agentsOrganic active ingredientsChemical synthesisOxygen
The invention relates to a compound for inhibiting the growth of tubercle bacillus and a preparation method thereof, belonging to the field of chemical synthesis. The invention provides 1-ethyl-4-hydroxy-2-oxygen-N'-trideformoxyl-1,2-dihydroquinoline-3-formylhydrazine with the structure of general formula (I) or pharmaceutically acceptable nontoxic salt thereof aiming at more and more serious epidemic situation of tuberculosis and the occurrence of multiple-drug resistant tuberculosis. In vitro tubercle bacillus inhibition tests verify that the compound of the invention can effectively inhibit the growth of tubercle bacillus, the MIC (Minimal Inhibitory Concentration) range is 0.4-2 mu g / ml, and moreover, the compound also has obvious inhibition effects on the growth of multiple-drug resistant tubercle bacillus in clinic.
Owner:FUDAN UNIV
Biological agent for treating drug-resistant tuberculosis and preparation method thereof
ActiveCN107812013BImprove the quality of lifeAppetite weight gainCulture processUnknown materialsAntigenLymphocyte culture
Owner:苏州市第五人民医院
Pharmaceutical application of N-(thiophene-2)amide derivatives in pyrazinamide-resistant tuberculosis and tuberculosis therapy
InactiveCN106117161AInhibit Mycobacterium tuberculosisInhibitory activityAntibacterial agentsOrganic active ingredientsRibosomal proteinMedicine
The present invention discloses ribosomal protein S1(RpsA) with structural N-(thiophene-2)amide derivatives (formula (1)) antagonistic ribosome 30S small subunits, and the protein can effectively inhibit the growth of Mycobacterium tuberculosis and pyrazinamide-resistant Mycobacterium tuberculosis and can be used to prepare drugs for treating pyrazinamide-resistant tuberculosis and tuberculosis.
Owner:CHINA PHARM UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com